Full-year EPS guidance raised to 8-10% growth
Guidance · revenue to 4%
Mettler-Toledo reported Q1 results in line with expectations, with 3% organic LC sales growth and strong EPS growth of 9%. Management remained cautious on the macro environment due to geopolitical tensions and tariffs but raised full-year EPS guidance slightly, citing confidence in H2 improvement driven by China and bioprocessing. Q1 LC sales grew 3% (1% organic ex-acquisitions), with EPS up 9% to $8.91.
Mettler-Toledo reported Q1 results in line with expectations, with 3% organic LC sales growth and strong EPS growth of 9%. Management remained cautious on the macro environment due to geopolitical tensions and tariffs but raised full-year EPS guidance slightly, citing confidence in H2 improvement driven by China and bioprocessing. Q1 LC sales grew 3% (1% organic ex-acquisitions), with EPS up 9% to $8.91.
Guidance · revenue to 4%
Management acknowledged increased macro uncertainty and customer delays but expressed confidence in obtaining solid EPS growth driven by innovation and cost execution, with a gradual improvement expected in the second half.
Full-year LC sales growth guidance maintained at ~4% (incl. ~0.8% acquisition contribution), while EPS guidance raised slightly to $46.30-$46.95 (8-10% growth) from $46.30-$46.95.
China industrial momentum builds with third consecutive quarter of growth. Management acknowledged increased macro uncertainty and customer delays but expressed confidence in obtaining solid EPS growth driven by innovation and cost execution, with a gradual improvement expected…
China industrial momentum builds with third consecutive quarter of growth. Management acknowledged increased macro uncertainty and customer delays but expressed confidence in obtaining solid EPS growth driven by innovation and cost execution, with a gradual improvement expected in the second half.
Management acknowledged increased macro uncertainty and customer delays but expressed confidence in obtaining solid EPS growth driven by innovation and cost execution, with a gradual improvement expected in the second half.
“our guidance includes a benefit from changes to U.S. import tariff rates in February, but also assumes tariffs in the second half of the year return to consistent levels with prior IEPA rates”
“it's a combination of the Ukraine and the Middle East. I mean, the old prices, we all know, went up quite significantly. And the weakness in chemical actually, we saw some of that in our process analytics business”
“Our liquid handling business also recently became first to market with low retention pipette chips that do not use PFAS or forever chemicals.”
| 지표 | 기간 | 범위 | 중간값 | 상태 |
|---|---|---|---|---|
| EPS | FY2026 | $46.30–$46.95 | $46.62 | RAISED |
| EPS | FY2026 Q2 | $10.70–$10.85 | $10.77 | GUIDED |
| Free cash flow | FY2026 | $900M | $900M | GUIDED |
| Revenue | FY2026 | 4% | 4% | MAINTAINED |
| Revenue | FY2026 Q2 | 3% | 3% | GUIDED |
1 of 1 · 평균 편향 +6.4%